On Tuesday, Shares of Jack in the Box Inc. (NASDAQ:JACK), lost -1.67% to $85.94.
Jack in the Box, declared the launch of the NEW Portobello Mushroom BUTTERY JACK. This mouthwatering burger is the newest craveable offering from the popular BUTTERY JACK line and features flavorful Portobello mushrooms, creamy peppercorn mayo, grilled onions, Swiss cheese and melted garlic herb butter atop a quarter-pound signature beef patty, served on Jack’s gourmet signature bun.
The Portobello Mushroom BUTTERY JACK joins its BUTTERY JACK predecessors, the Classic BUTTERY JACK, which features creamy tomato sauce, green leaf lettuce, fresh tomatoes and Provolone cheese, and Bacon & Swiss BUTTERY JACK, which features creamy bacon mayo, hickory smoked bacon and Swiss cheese.
“The Portobello Mushroom BUTTERY JACK is a tasty addition to our BUTTERY JACK line,” said Iwona Alter, Jack in the Box Vice President of Menu Strategy & Innovation. “The Portobello mushrooms add a rich layer of flavor that we hope our guests will love and crave throughout the summer and into fall.”
Jack in the Box Inc. operates and franchises Jack in the Box quick-service restaurants and Qdoba Mexican Grill fast-casual restaurants in the United States. As of February 17, 2015, it operated about 2,200 restaurants in 21 states and Guam; and operated and franchised 600 Qdoba Mexican Grill restaurants in 47 states, the District of Columbia, and Canada.
Shares of Callon Petroleum Company (NYSE:CPE), inclined 0.92% to $8.74, during its last trading session.
Callon Petroleum Company, stated results of operations for the three and six month periods ended June 30, 2015.
Key highlights for the second quarter of 2015 comprise:
- Net daily production of 9,516 barrels of oil equivalent per day (“BOE/d”), an enhance of 11% contrast to the first quarter of 2015, comprised of 79% oil volume
- Lease operating costs, counting workovers, of $7.59 per barrel of oil equivalent (“BOE”), a decrease of 16% contrast to the first quarter of 2015
- Adjusted EBITDA, a non-GAAP financial measure(i), of $31.7 million, an enhance of 14% contrast to the first quarter of 2015
- Adjusted income accessible to common shareholders, a non-GAAP financial measure(i), of $0.04 per diluted share based on total average diluted shares outstanding of 66.0 million shares
- Raised annual production guidance midpoint by 6% to 9,600 BOE/d and established third quarter 2015 production guidance midpoint at 9,800 BOE/d
Callon Petroleum Company engages in the exploration, development, acquisition, and production of oil and natural gas properties in the Permian Basin in West Texas. As of December 31, 2014, its estimated net proved reserves totaled 32.8 million barrel of oil equivalent, counting 25.7 million barrels of oil and 42.5 billion cubic feet of natural gas.
At the end of Tuesday’s trade, Shares of TherapeuticsMD Inc (NYSEMKT:TXMD), gained 0.62% to $6.49.
TherapeuticsMD, declared that the U.S. Patent and Trademark Office allowed patent application 14/136,048 related to TX-004HR, the company’s phase 3 drug candidate for the treatment of vulvar and vaginal atrophy (VVA), which utilizes the company’s SYMBODA technology.
The newly allowed patent application relates to solubilized compositions encapsulated in vaginal suppositories for local delivery of bio-identical estradiol and establishes an important IP foundation for TX-004HR.
“Women and physicians are looking for alternatives for the treatment of VVA with lower systemic exposure of estradiol,” said TherapeuticsMD CEO Robert G. Finizio. “Having this patent allowance significantly enhances the value of TX-004HR, which is being studied in our phase 3 Rejoice Trial for the treatment of moderate to severe dyspareunia, as a symptom of VVA due to menopause.”
TherapeuticsMD, Inc. operates as a women’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, counting prenatal vitamins, iron supplements, vitamin D supplements, and natural menopause relief products under the vitaMedMD brand, in addition to duplicate formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name.
Finally, Ralph Lauren Corp (NYSE:RL), ended its last trade with -0.64% loss, and closed at $117.23.
Ralph Lauren Corporation, stated net income of $95 million, or $1.09 per diluted share, for the first quarter of Fiscal 2016, which excludes restructuring and non-cash charges associated with its global brand reorganization. This contrast to net income of $162 million, or $1.80 per diluted share, for the first quarter of Fiscal 2015. On a stated basis, net income was $64 million or $0.73 per diluted share in the first quarter. The Company also declared noteworthy progress on the transition to the new global brand administration organizational structure.
First Quarter 2016 Income Statement Review
Net Revenues. Net revenues for the first quarter of Fiscal 2016 were in line with the preceding year period on a constant currency basis, driven by double-digit growth internationally, contribution from new stores and global e-commerce expansion. Stated net revenues declined 5% to $1.6 billion in the first quarter. The decline in stated net revenues comprised of about 500 basis points of negative impact from foreign currency effects.
Wholesale Sales. In the first quarter of Fiscal 2016, wholesale segment sales declined 6% on a constant currency basis. Wholesale revenue in the first quarter was negatively influenced by our customers’ receipt plans due to an earlier Easter this year which was partially offset by double-digit constant currency growth in Europe. Combining 4Q15 and 1Q16, which is more reflective of the Spring/Summer season, global wholesale revenues were up about 2% in constant currency. Stated wholesale segment sales declined 9% to $642 million.
Retail Sales. Retail sales raised 3% on a constant currency basis in the first quarter over the preceding year period, driven by contribution from new stores and e-commerce expansion. Stated retail sales declined 3% contrast to the first quarter of Fiscal 2015 to $935 million, negatively influenced by foreign currency movements. Merged comparable store sales reduced 2% on a constant currency basis during the first quarter and declined 8% on a stated basis.
Licensing. Licensing revenues of $41 million in the first quarter were 6% above the preceding year period in constant currency and grew 3% on a stated basis, reflecting higher royalties from raised sales of Ralph Lauren, Polo and Lauren products worldwide.
Gross Profit. Gross profit for the first quarter of Fiscal 2016 was $969 million and gross profit margin was 59.8%, not taking into account restructuring-related non-cash charges of $3 million. Gross profit margin was 120 basis points lower than the preceding year period, reflecting unfavorable foreign currency effects.
Operating Expenses. Not taking into account restructuring and related non-cash charges, operating expenses were $828 million in the first quarter of Fiscal 2016, 4% above the preceding year period. Operating expense rate of 51.1% raised 430 basis points contrast with the first quarter of Fiscal 2015, due to the timing of revenue receipts and incremental investments in infrastructure. As stated, operating expenses in the first quarter of Fiscal 2016 were $870 million, which comprised of $42 million in restructuring and non-cash charges associated with our global brand reorganization.
Ralph Lauren Corporation designs, markets, and distributes lifestyle products worldwide. The company operates in three segments: Wholesale, Retail, and Licensing. It offers apparel, counting a range of men’s, women’s, and children’s clothing; accessories, which comprise footwear, eyewear, watches, fine jewelry, hats, belts, and leather goods, such as handbags and luggage; home products compriseing of bedding and bath products, furniture, fabrics and wallpapers, lightings, paints, tabletops, and giftware; and fragrances
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
